Clinical trials
Recruiting Phase 1 Leukemia, Myeloid, Acute trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
169 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 6 |
| 2021 | 7 |
| 2022 | 13 |
| 2023 | 18 |
| 2024 | 39 |
| 2025 | 42 |
| 2026 | 30 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 169 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| City of Hope Medical Center | 10 |
| M.D. Anderson Cancer Center | 9 |
| Dana-Farber Cancer Institute | 5 |
| National Cancer Institute (NCI) | 5 |
| Zhejiang University | 5 |
| Institute of Hematology & Blood Diseases Hospital, China | 4 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Fred Hutchinson Cancer Center | 3 |
| Montefiore Medical Center | 3 |
| OHSU Knight Cancer Institute | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 169 |
| Myelodysplastic Syndromes | 52 |
| Leukemia | 20 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 18 |
| Recurrence | 18 |
| Hematologic Neoplasms | 12 |
| Leukemia, Myelomonocytic, Chronic | 10 |
| Leukemia, Biphenotypic, Acute | 7 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 7 |
| Leukemia, Myeloid | 7 |
Trials
Showing 1 to 25 of 169. Each trial links to its page on Pharma Observatory.
69 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.